Evaluation of Atrial Electromechanical Delay in Children with Obesity

Fatih Temiz1, Hatice Güneş2, Hakan Güneş3

  • 1Sutcu Imam University, Department of Pediatric Endocrinology, 46100 Kahramanmaras, Turkey. ftemiz2003@yahoo.com.

Insights

Obese children show prolonged electromechanical delay (EMD), a predictor of atrial fibrillation. Increased body mass index (BMI) in these children is linked to longer EMD, suggesting a heightened cardiovascular risk.

Area of Science:

  • Cardiology
  • Pediatrics
  • Biomedical Engineering

Background:

  • Childhood obesity is a growing global health concern.
  • Obesity is linked to increased morbidity, mortality, and cardiovascular diseases.
  • Electromechanical delay (EMD) is a known predictor of atrial fibrillation (AF).

Purpose of the Study:

  • To investigate if electromechanical delay (EMD) is prolonged in obese children.
  • To determine the relationship between body mass index (BMI) and EMD in pediatric obesity.
  • To assess EMD as a potential risk factor for cardiovascular issues in obese youth.

Main Methods:

  • The study included 59 obese children (8-18 years) and 38 healthy controls.
  • Transthoracic echocardiography and tissue Doppler imaging were used.
  • Measurements included left ventricular function and inter-/intra-atrial EMD.

Main Results:

  • Obese children exhibited significantly longer P-wave to diastolic wave intervals (PA lateral, PA septum) and inter-/intra-atrial EMD compared to controls (p < 0.001).
  • Inter-atrial EMD and intra-atrial EMD positively correlated with BMI (r = 0.484, p < 0.001 and r = 0.376, p = 0.001, respectively).
  • BMI was a significant independent predictor of inter-atrial EMD (β = 0.473, p < 0.001).

Conclusions:

  • Electromechanical delay is significantly increased in obese children compared to healthy controls.
  • Intra- and inter-atrial EMD are correlated with body mass index in obese children.
  • BMI is an independent predictor of inter-atrial EMD in this pediatric population.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.2K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
238
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
265
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
260
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
175
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
492